The trajectory of copyright's flagship drug presents a nuanced case for stakeholders in the drug sector. While initially a phenomenal success, generating vast sums, the exclusivity end and the subsequent arrival of cheaper versions have significantly affected income. This raises questions about the long-term profitability of related drug developmen